Sigma Oman: Independents not making MUR claims

News

Sigma Oman: Independents not making MUR claims

Independent pharmacies in England claimed just £11.6 million out of a possible £24.8 million in medicines use review (MUR) payments between September 2017 and September 2018, according to data revealed during the Sigma conference in Oman.

The latest figures from the NHS Business Services Authority showed that independents lagged behind other pharmacy sectors when it came to claiming the payments.

Regional chains took £9.3 million from a total of £12.3 milion, managed chains recorded £19.7 million from £20.5 million, the national multiples claimed £4.5 million from £4.7 million and supermarkets took £3.4 million from £3.8 million.

"Independents are taking 47% of available funds. I don't know why that is but only 47% of funding is being claimed by independents," said Carole Alexandre, vice-president global services at IQVIA.

"Every other sector has increased over the last 12 months. Managed chains have gone from 87% to 97%."

However, in terms of the electronic prescription service (EPS), independents were perfoming relatively well compared with the other pharmacy sectors, with 67.5% of EPS items, the same as the regional chains, better than the managed chains (66.8%) and supermarkets (58.4%) and slightly worse than the national multiples (69.3%).

Alexandre also revealed the UK generic market is worth £2.4 billion of which almost 10% is made up of generic concessionary products. Independents had 37.1% of the concessionary value share and 34.9% of the concessionary volume share. 

 

Record my learning outcomes

News

Share: